Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement
AT-Konsensus · 2020 · Austria
Source and licence
- Authors
- Diana Bonderman, Gerhard Pölzl, Klemens Ablasser et al.
- Title
- Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement
- Journal
- Wiener Klinische Wochenschrift, 2020
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC7732807
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatment, and structured patient care. This requires intensive collaboration across several disciplines, and between resident physicians and specialized centers. The aim of this consensus statement is to provide guidance for the rapid and efficient diagnosis and treatment of light-chain amyloidosis and transthyretin amyloidosis, which are the most common forms of cardiac amyloidosis.
Contents of the original publication
The section headings of the original.
- Introduction
- Epidemiology
- AL amyloidosis
- ATTR amyloidosis
- Key messages
- Pathophysiology
- AL amyloidosis
- ATTR amyloidosis
- Key messages
- Clinical presentation
- Signs indicating the cause of cardiac amyloidosis
- Key messages
- Diagnostic algorithm
- Step 1 (first visit)
- Step 2 (primary care provider and/or specialized center)
- Step 3 (specialized center)
- Key messages
- Diagnostic methods
- Step 1: electrocardiography, echocardiography, and magnetic resonance imaging
- Key messages
- Step 2: laboratory tests and scintigraphy
- Key messages
- Step 3: biopsy and genetic testing
- Key messages
- Risk stratification
- Key messages
- Which patients should be screened for cardiac amyloidosis?
- All patients with established or suspected non-cardiac amyloidosis
- Patients with a hypertrophic cardiac phenotype of unknown origin
- Key messages
- Treatment options
- Supportive therapies
- Key messages for supportive therapies
- Amyloid-specific therapies
- Transplantation
- Key messages on specific therapies
- Long-term care
- Key message
- Support group, AIDA registry
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint